Evidence map›Paper›PMID 39203346›Full record

ArticleMicroorganisms2024

High-Throughput Screening Assay for Convalescent Sera in COVID-19: Efficacy, Donor Selection, and Variant Neutralization.

Krishna P Kota, Ilya Trakht, Gavreel Kalantarov, David Ordonez, Jiayi Wei, Stephanie Trefry, Evia Bavari, Jenny Richardson, Rouzbeh Zamani, Christy Raney and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Krishna P KotaTonix Pharmaceuticals, Frederick, MD 21701, USA.
Ilya TrakhtDepartment of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Gavreel KalantarovDepartment of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
David OrdonezTonix Pharmaceuticals, Frederick, MD 21701, USA.
Jiayi WeiTonix Pharmaceuticals, Frederick, MD 21701, USA.
Stephanie TrefryTonix Pharmaceuticals, Frederick, MD 21701, USA.
Evia BavariTonix Pharmaceuticals, Frederick, MD 21701, USA.
Jenny RichardsonTonix Pharmaceuticals, Frederick, MD 21701, USA.
Rouzbeh ZamaniTonix Pharmaceuticals, Frederick, MD 21701, USA.
Christy RaneyTonix Pharmaceuticals, Frederick, MD 21701, USA.
Farooq NasarTonix Pharmaceuticals, Frederick, MD 21701, USA.
Bruce DaughertyTonix Pharmaceuticals, Frederick, MD 21701, USA.
Seth LedermanTonix Pharmaceuticals, Frederick, MD 21701, USA.ORCID 0000-0003-2781-1455
Sina BavariTonix Pharmaceuticals, Frederick, MD 21701, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Convalescent sera, rich in pathogen-specific antibodies, offers passive immunity to patients with infectious diseases. Screening assays using convalescent sera are crucial for evaluating therapeutic efficacy, selecting suitable serum donors, and standardizing assays. They measure antibody levels, neutralizing potential, and specificity against viruses like SARS-CoV-2, ensuring therapeutic serum contains potent antibodies. Standardized procedures enable reliable results and wider adoption of serum therapy for COVID-19. We have developed a high-content image-based assay for screening convalescent sera against SARS-CoV-2 variants. Using various cell lines, we identified optimal candidates, employed immunofluorescence to visualize infected cells, and assessed neutralizing antibody efficacy. Screening convalescent sera for therapeutic potential identified neutralizing activity against SARS-CoV-2 variants. Dose-response analysis showed variable neutralizing activity, with some sera exhibiting broad neutralization. Additionally, we explored the synergy between neutralizing sera and β-d-N4-hydroxycytidine (NHC), an initial metabolite of molnupiravir. These assays enhance serum therapy's benefits for COVID-19 treatment and aid in understanding neutralizing activity against SARS-CoV-2 variants, addressing viral challenges.

Indexed as

convalescent serahigh-content imagingSARS-CoV-2

Identifiers

PMID39203346
PMCPMC11355970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.